Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine
Abstract.: Several lines of evidence suggest that cholinergic deficits may contribute to the pathophysiology of psychiatric disorders as well as Alzheimer’s disease. There is growing clinical evidence that galantamine, currently used for the treatment of Alzheimer’s disease, may improve cognitive dy...
Main Authors: | Yukio Ago, Ken Koda, Kazuhiro Takuma, Toshio Matsuda |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2011-01-01
|
Series: | Journal of Pharmacological Sciences |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1347861319307145 |
Similar Items
-
Galantamine-Curcumin Hybrids as Dual-Site Binding Acetylcholinesterase Inhibitors
by: Georgi Stavrakov, et al.
Published: (2020-07-01) -
A galantamine–curcumin hybrid lacks the depressant side effect of acetylcholinesterase inhibitors
by: Ivanka Kostadinova, et al.
Published: (2024-01-01) -
Galantamine Based Novel Acetylcholinesterase Enzyme Inhibitors: A Molecular Modeling Design Approach
by: Luciane B. Silva, et al.
Published: (2023-01-01) -
Preventive Effects of an Enriched Environment on Rodent Psychiatric Disorder Models
by: Kazuhiro Takuma, et al.
Published: (2011-01-01) -
The Potential Role of Serotonin1A Receptors in Post-weaning Social Isolation–Induced Abnormal Behaviors in Rodents
by: Yukio Ago, et al.
Published: (2014-01-01)